360 likes | 364 Views
AML Research Focus: Exploring New Treatment Options.
E N D
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Venetoclax + Hypomethylating Agents Treatment-Naive Older AML, Phase 1b
Venetoclax Plus Low-Dose Cytarabine Treatment-Naive Older AML
Vadastuximab Talirine (SGN-CD33A) + HMAsOlder Patients With Treatment-Naive AML
Vadastuximab Talirine Plus 7+3 Induction Therapy for ND AML, Phase 1b